Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 9, Issue 10, Pages 1289-1297Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17512433.2016.1232164
Keywords
Orlistat; phentermine/topiramate; Qsymia; naltrexone/bupropion; Contrave; Iorcaserin; Belviq; Iiraglutide; Saxenda
Categories
Ask authors/readers for more resources
Introduction: Obesity is a major health concern for several countries. The United States (U.S.) has arguably led the world in the percentage of overweight and/or obese per capita for several decades. As a result, numerous FDA-approved pharmacotherapeutic options are available for the long-term treatment of obesity. Although most of these medications have been on the U.S. market for a few years and have demonstrated efficacy for long-term weight loss in clinical trials, the impact of these medications on obesity in the U.S. has yet to be realized. Areas covered: We will review and evaluate why pharmacotherapy for obesity has not produced a meaningful reduction in the number of overweight and obese adults in the U.S. Expert commentary: Several obstacles, such as adverse drug effects, poor insurance coverage, not treating obesity as a chronic disease, and availability of other weight loss alternatives, has resulted in poor performance of pharmacotherapy for obesity in the U.S. market.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available